Neoadjuvant Chemoimmunotherapy Complicates Subsequent Surgical Resection and Adjuvant Immunotherapy Is Preferable From the Surgical Standpoint

J Thorac Oncol. 2024 Jun;19(6):858-861. doi: 10.1016/j.jtho.2024.02.009.

Authors

Paula Ugalde Figueroa¹, Valérie Lacroix², Paul E Van Schil³

Affiliations

¹ Department of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Department of Cardiothoracic Surgery, Université Catholique de Louvain (UCL), Brussels, Belgium.
³ Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Antwerp, Belgium. Electronic address: paul.van.schil@uza.be.

PMID: 38849165
DOI: 10.1016/j.jtho.2024.02.009

No abstract available

Publication types

Editorial

MeSH terms

Humans
Immunotherapy*
Lung Neoplasms* / therapy
Neoadjuvant Therapy*